Trivieri, Nadia
Pracella, Riccardo
Cariglia, Maria Grazia
Panebianco, Concetta
Parrella, Paola
Visioli, Alberto
Giani, Fabrizio
Soriano, Amata Amy
Barile, Chiara
Canistro, Giuseppe
Latiano, Tiziana Pia
Dimitri, Lucia
Bazzocchi, Francesca
Cassano, Dario
Vescovi, Angelo L.
Pazienza, Valerio
Binda, Elena http://orcid.org/0000-0002-8750-2905
Funding for this research was provided by:
Ministero della Salute (GR-2011-02351534, Progetto Ricerca Corrente 2018-20)
Associazione Italiana per la Ricerca sul Cancro (IG2019-ID23006, IG2018-ID22027)
Article History
Received: 12 October 2020
Accepted: 4 December 2020
First Online: 14 December 2020
Ethics approval and consent to participate
: Patients with a confirmed diagnosis of CRC and healthy subjects included in the control group were enrolled in this study at IRCCS “Casa Sollievo della Sofferenza” Hospital, under the Ethical committee approvals number N.175/CE and N.94/CE. All the subjects agreed to participate according to the ethical guidelines of the 2013 Declaration of Helsinki and signed an informed consent for samples and anonymized information to be used. All the experimental procedures for the in vivo mice studies have been approved by the Ministry of Health (PR/15–297/2019-PR).
: All authors have seen and approved the manuscript and consent publication.
: The authors declare no competing financial interests. ALV has ownership interest in Stemgen Spa.